Delta4 Identifies a Potential New Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS) using computational Hyper-C Drug Discovery Platform
Delta4, a pioneering digital drug discovery company specializing in identifying new therapeutic indications for drugs with established safety profiles, has made a promising breakthrough in the search for novel...